This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
DosingEfficacy & Safety Data Efficacy &
Safety Data EfficacySafety ProfileSearch

Menu

Close

SamplesResources

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PVC-USA-0989
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. PP-MCL-USA-0367

​​​​​​​
INDICATION

Premarin® (conjugated estrogens) Vaginal Cream is indicated for the treatment of atrophic vaginitis and kraurosis vulvae; and for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. 

In a prespecified secondary endpoint,

Overall vaginal health was assessed at baseline and week 122

  • Total composite scores‡ increased with Premarin Vaginal Cream from 10.78 to 16.31 (n=139) vs 10.09 to 11.76 with placebo (n=68)

    -​​​​​​​​​​​​​​A total score of ≤15 is consistent with moderate to severe vaginal atrophy 
 

Overall vaginal health was a total composite score of:

  • Moisture
  • Epithelial mucosa
  • Fluid secretion
  • Vaginal rugosity
  • Vaginal pH
  • Mucosa color 

No conclusions can be made regarding significance or the individual components comprising the total composite score.

‡Genital Health Clinical Evaluation is a tool used to measure overall vaginal health by using a total composite score of the parameters listed above. Individual components were not analyzed separately.